A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis

Annals of Dermatology

Volumn 22, Issue 2, 2010, Pages 138-142

  Lee, Eun Ju ^a   Shin, Min Kyung ^a   Kim, Nack In ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Cyclosporine; Etanercept; Refractory psoriasis

Indexed keywords

EID: 77954692375     PISSN: 10139087     EISSN: None     Source Type: Journal    
DOI: 10.5021/ad.2010.22.2.138     Document Type: Article

References (15)

1. Gudijonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Palier AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 7th ed. New York: McGraw-Hill, 2008: 169-198.
2. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139: 1627-1632.
3. Stebbins WG, Lebwohl MG. Biologies in combination with nonbiologics: efficacy and safety. Dermatol Ther 2004; 17: 432-440.
4. Lago E, Carneiro S, Cuzzi T, Magalhaes G, Cassia F, Pessanha F, et al. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. J Cutan Pathol 2007;34: 15-21.
5. Berth-Jones J. The use of ciclosporin in psoriasis. J Dermatolog Treat 2005;16: 258-277.
6. Goldsmith DR, Wagstaff AJ. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Am J Clin Dermatol 2005;6: 121-136.
7. Isnard Bagnis C, Tezenas du Monteei S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002;13: 2962-2968.
8. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996;35: 710-719.
9. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003;49:S118-124.
10. Costanzo A, Talamonti M, Spallone G, Borti E, Chimenti MS, Papoutsaki M, et al. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 2009;218: 146-150.
11. Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26: 1127-1129.
12. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146: 118-121.
13. GuI U, Gonul M, Kilic A, Erdem R, Cakmak SK, Gunduz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clin Ther 2006;28: 251-254.
14. Javier P, Esteban D, Tatiana S, Amaro G. Cyclosporin A effectively controls recalcitrant psoriasis resistant to biologic therapy. J Am Acad Dermatol 2007;56: AB180.
15. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45: 953-956.